Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza
NCT ID: NCT01037205
Last Updated: 2014-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
264 participants
INTERVENTIONAL
2009-12-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influenza Antiviral DAS-181-F04 in Healthy Adults
NCT01651494
Influenza Antiviral DAS181-F03
NCT01173224
Single Dose Escalating Study of DAS181 in Adults
NCT00527865
DAS181 Single Dose Escalation Study in Healthy Adults
NCT00876161
Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults
NCT02350751
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Based upon a Rapid Diagnostic Test of IFV, subjects will be randomized into one of three groups: a single dose DAS181 10 mg group, a multiple dose DAS181 10 mg, 10 mg, 10 mg dose group or a placebo group.
The full analysis set will include subjects with confirmed influenza as documented with Rapid Diagnostic Testing. The set will be used for activity analysis and will include all randomized subjects with baseline and treatment data. Study staff may visit subjects outside the clinic. Per protocol, the safety analysis sets are described below in Statistical Methods.
Peripheral venous blood samples for pharmacokinetic (PK) and immunogenic analysis of DAS181 will be obtained on 10 subjects enrolled in each study arm.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DAS181 High Dose
DAS181 Dry Powder 10 mg qd x 3 days
DAS181 dry powder, formulation F02
10 mg delivered dose DAS181 in clear HPMC #3 Capsules
DAS181 Low Dose
DAS181 Dry Powder 10 mg Day 1 Lactose Placebo Day 2 and Day 3
DAS181 dry powder, formulation F02
10 mg delivered dose DAS181 in clear HPMC #3 Capsules
Lactose Placebo
Lactose (Respitose ML006 (DMV-Fonterra)) 1 capsule qd x 3 days
Respitose ML006 (DMV-Fonterra)
Lactose monohydrate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DAS181 dry powder, formulation F02
10 mg delivered dose DAS181 in clear HPMC #3 Capsules
Respitose ML006 (DMV-Fonterra)
Lactose monohydrate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects must be able to verbalize understanding of the consent form, provide written informed consent and verbalize willingness to complete study procedures.
3. Be 18 to 70 years of age (inclusive).
4. Subjects must weigh at least 55 kg and must have a Body Mass Index (BMI) of no greater than 35.99
5. Febrile, oral temperature \>100°F (37.8°C) and one or more of the following:
* Respiratory symptom (cough, sore throat, nasal symptoms)
* Constitutional symptom (headache, myalgia, sweat/chills, prostration)
6. Positive rapid antigen test (RAT) for influenza performed using FDA-Cleared and CLIA-Waived commercially available rapid antigen test. A subject may be enrolled following a positive RAT of any manufacturer. Test may be conducted by a primary care physician prior to study enrollment if documentation of a positive RAT can be provided (documentation may consist of subjects medical records and must be included in subject documentation). A subject with a negative RAT result may still enroll if the sponsor and investigator agree that there is a known influenza outbreak circulating in the community. Blood pressure within normal limits (systolic 90-150 mmHg; diastolic 50-95 mmHg) and heart rate between 45 and 140 beats per minute.
7. Blood pressure within normal limits (systolic 90-150 mmHg; diastolic 50-95 mmHg) and heart rate between 45 and 140 beats per minute.
8. Onset of illness no more than 48 hours prior to diagnosis. Note: Time of onset of illness is defined as either (1) the time when the temperature was first measured as elevated (at least one degree (°C) of elevation temperature), OR (2) the time when the subject experienced the presence of at least one respiratory symptom or the presence of at least one constitutional symptom.
9. Female subjects must be post-menopausal (one year or greater without menses), surgically incapable of childbearing, practicing abstinence or practicing two effective methods of birth control. Acceptable methods may include intrauterine device, spermicide, barrier and hormonal contraception. A female subject must agree to practice an acceptable method of birth control during study period and for 12 weeks after study terminates. All female subjects regardless of menopausal status or surgical history must have had a negative urine pregnancy test (urine betahuman chorionic gonadotropin \[hCG\]) during the screening visit. The urine pregnancy test must be sensitive to at least 50 mU/mL of beta-hCG.
10. Male subjects must agree to use a medically accepted form of contraception from time of enrollment to 12 weeks after study termination.
Exclusion:
1. Have received any investigational drug or vaccine within 8 weeks prior to study drug dosing.
2. Have had a serious adverse reaction or hypersensitivity to any drug.
3. Have received blood products within 6 months of study enrollment.
4. Have concurrent cystic fibrosis, emphysema or previous episodes of anaphylaxis.
5. Have sickle-cell disease.
6. Allergy or history of allergy to milk or lactose.
7. Any history of congenital or acquired bleeding abnormalities.
8. Existence of any surgical, medical, or laboratory condition that, in the judgment of the clinical investigator, might interfere with the safety, distribution, metabolism or excretion of the drug.
9. Use of antiviral influenza medications within 10 days prior to screening (subjects will be prohibited from taking antiviral influenza medications during the course of the trial).
10. Current clinical evidence of a recognized or suspected uncontrolled non-influenza infectious illness with onset prior to screening.
11. Known hypersensitivity to DAS181.
12. Women who are pregnant (urine pregnancy test), who are attempting to become pregnant, or who are breast-feeding.
13. Uncontrolled seizure disorder or history of seizure activity within 12 months prior to study participation.
14. Any significant findings in the subject's medical history or physical examination that, in the opinion of the investigator, would affect subject safety or compliance with the dosing schedule.
15. Documented infection other than IFV in past 2 weeks.
16. Subjects with previous or current history of asthma or COPD requiring acute or chronic medication.
17. Subjects with acute diagnosis of a chronic medical condition within the last 3 months.
18. Subjects with a chronic medical condition that have initiated or changed dosing or regimen of prescription medications for their chronic medical condition within the last 3 months (any changes in chronic medications during the 28 day enrollment period will be captured in the source documentation under concomitant medications).
19. Subjects with previous or current history of the following systemic disorders: immunological disorders, HBV, HCV or cirrhosis, transplant recipients, HIV infection, or other immunosuppressive illness.
20. Subjects with cancer or history of hematologic malignancy. Cancer is defined as any active neoplastic diseases excluding noninvasive basal cell carcinoma.
21. Subjects who have had or are scheduled to have surgery within 30 days of initiation of the study.
22. Subjects who have donated or lost more than 500 mL of blood in the two months prior to screening.
23. Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Ansun Biopharma, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald Moss, MD
Role: STUDY_DIRECTOR
Ansun Biopharma, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Carmichael, California, United States
Chula Vista, California, United States
La Mesa, California, United States
Lincoln, California, United States
Los Angeles, California, United States
Orange, California, United States
Colorado Springs, Colorado, United States
Denver, Colorado, United States
Hialeah, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Boise, Idaho, United States
Covington, Louisiana, United States
Silver Spring, Maryland, United States
North Dartmouth, Massachusetts, United States
Bellevue, Nebraska, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Stony Brook, New York, United States
Canton, Ohio, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Groveport, Ohio, United States
Miamisburg, Ohio, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
Ashland, Oregon, United States
Lansdale, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Myrtle Beach, South Carolina, United States
Simpsonville, South Carolina, United States
Rapid City, South Dakota, United States
Johnson City, Tennessee, United States
Austin, Texas, United States
Georgetown, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
West Point, Utah, United States
West Valley City, Utah, United States
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 2012 Dec 15;206(12):1844-51. doi: 10.1093/infdis/jis622. Epub 2012 Oct 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HHSN266200600015C
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
DAS181 - 2 - 03 (DMID 09-0090)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.